Authors: Der Madiagne, Niang Aissatou Ahmet, Diop Amadou, Diallo Fatoumata, Sarr Habib, Dieye Baidy, Kâ Rougyatou, Dia Mouhamadou Lamine.
Objective: Hepatitis B is a liver infection that is widespread throughout the world and constitutes a real public health problem, with 2 billion people infected by the virus worldwide. The aim was to study the prevalence of Hepatitis B virus (HBV) markers in patients received at the Bacteriology-Virology laboratory of CHNU of FANN.
Methodology: This is a retrospective study based on the exploitation of results covering the period from January to November 2020. The markers included in our study were: HBs antigen (HBsAg); anti HBs antibody (anti HBsAb); HBe antigen (HBeAg); anti HBe antibody (anti HBeAb); anti HBc antibody (anti HBcAb). The data were collected from registers, then entered and processed using EPI-INFO software version 3.5.4.
Results: 1,590 patients were seen during the study period for serological markers of hepatitis B virus. The mean age was 41.90 years, with extremes of 2 years and 100 years. Women accounted for 55.98%, giving a sex ratio (M/F) of 1.27. The age group [20-40 years] was the most representative of our study population with a percentage of 47.9%, followed by the age group 40-60 years with a percentage of 23.9%. The prevalence of HBsAg-positive patients was 11.1%, HBeAg-positive patients 9.15%, HBeAb-positive patients 66.1% and HBcAb-positive patients 68.5%; 59.92% of patients had an anti-HBs antibody titre above the protective threshold (greater than 10 IU/L). Seroprevalence was higher in women than in men, with 49.37% in men and 50.63% in women, i.e. a total of 79 men for 81 women.
View/Download pdf